S-23 (drug)

S-23 is a Selective Androgen Receptor Modulator (SARM) that was originally developed by GTX, Inc. for the treatment of muscle wasting, osteoporosis, and benign prostatic hypertrophy. S-23 is considered to be one of the more potent SARMs due to its very strong binding affinity for androgen receptors.

Pharmacology

S-23 is a non-steroidal SARM that binds to the androgen receptor with high affinity. It is tissue selective and has been shown to decrease prostate weight in rats with no significant decrease in muscle mass or anti-androgenic side effects. This suggests that S-23 does not have the negative side effects associated with traditional androgenic steroids such as suppression of natural testosterone production.

Clinical Use

While S-23 has not been approved for use in humans, it has been studied in animal models. These studies have shown that S-23 has the potential to increase muscle mass, reduce fat mass, and has a very high bioavailability. It is often used in the bodybuilding community due to its potential to increase lean muscle mass and strength.

Side Effects

Potential side effects of S-23 include suppression of natural testosterone production, mood changes, and changes in libido. However, these side effects are often considered to be less severe than those associated with traditional androgenic steroids.

Legal Status

S-23 is currently classified as a research chemical and is not approved for human consumption. However, it is often sold online as a dietary supplement.

See Also

• Selective Androgen Receptor Modulator
• GTX, Inc.
• Androgen receptor
• Androgenic steroids

‎